314 results match your criteria: "Centre hospitalier Annecy-Genevois[Affiliation]"

Ultra-low tidal volume ventilation for COVID-19-related ARDS in France (VT4COVID): a multicentre, open-label, parallel-group, randomised trial.

Lancet Respir Med

November 2023

Hospices Civils de Lyon, Croix-Rousse Hospital, Medical Intensive Care Unit, Lyon, France; Université de Lyon, Université Lyon 1, Lyon, France; CREATIS INSERM 1044 CNRS 5220, Lyon, France.

Background: COVID-19-related acute respiratory distress syndrome (ARDS) is associated with a high mortality rate and longer mechanical ventilation. We aimed to assess the effectiveness of ventilation with ultra-low tidal volume (ULTV) compared with low tidal volume (LTV) in patients with COVID-19-related ARDS.

Methods: This study was a multicentre, open-label, parallel-group, randomised trial conducted in ten intensive care units in France.

View Article and Find Full Text PDF
Article Synopsis
  • A study compared direct aortic cannulation to supra-aortic cannulation methods during surgery for type A aortic dissection to see which leads to better patient outcomes.
  • Data from 3,902 patients in the European registry showed that direct aortic cannulation resulted in lower in-hospital mortality (12.7% vs. 18.1%) and fewer postoperative complications, including issues like paralysis and infections.
  • The findings suggest that direct aortic cannulation is a safer option for patients undergoing surgery for acute type A aortic dissection.
View Article and Find Full Text PDF
Article Synopsis
  • The study aims to enhance myocardial injury assessment through detailed pixel-level analysis using advanced statistical tools, moving beyond traditional global descriptors like size and transmurality.
  • The research analyzed imaging data from 123 STEMI patients in the MIMI trial, comparing outcomes of immediate vs. delayed stenting, while utilizing statistical atlases for pixel-wise comparisons across patient groups.
  • Results indicated that, although global infarct measurements were similar between treatment approaches, delayed stenting showed more pronounced transmurality in specific heart regions, suggesting that detailed analysis can reveal significant local differences in myocardial injury.
View Article and Find Full Text PDF

Advances in antibacterial treatment of adults with high-risk febrile neutropenia.

J Antimicrob Chemother

September 2023

Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, F-75014 Paris, France.

Article Synopsis
  • High-risk febrile neutropenia (HR-FN) is a serious complication for patients dealing with blood cancers or certain chemotherapy treatments that requires updated management strategies, as significant advances have occurred in the last decade.
  • The study reviews literature from 2010 to 2023 focusing on antibiotic pharmacokinetics, initial dosing, and strategies for safely reducing or stopping antibiotics in HR-FN treatment.
  • Findings suggest that optimizing antibiotic dosages and using strategic discontinuation can improve patient outcomes and should be considered for future guidelines on HR-FN management.
View Article and Find Full Text PDF

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.

Leuk Res

July 2023

Hematology Department, Centre Léon Bérard, Lyon, France; INSERM U1052, CRCL, Lyon, France; French Group of CML (Fi-LMC), Lyon, France. Electronic address:

Article Synopsis
  • Accelerated phase chronic myeloid leukemia (AP-CML) has a poorer prognosis than chronic phase (CP-CML), prompting researchers to test second-generation tyrosine kinase inhibitors (TKI2) as an initial treatment due to their reduced toxicity.
  • In a study of 69 newly diagnosed patients with AP-CML, various health parameters were measured, revealing worse conditions in those with hematologic AP compared to cytogenetically defined AP.
  • Regardless of the type of TKI2 treatment used, the patients achieved similar rates of clinical response and overall survival, suggesting that TKI2 can effectively manage AP-CML and mitigate the challenges associated with its advanced disease phase.
View Article and Find Full Text PDF

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS-Mutant Lung Cancer.

J Thorac Oncol

October 2023

Respiratory Department and Early Phase, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Oncopharmacology Laboratory, Cancer Research Center of Lyon, Unité mixte de recherche (UMR) Institut national de la santé et de la recherche médicale (INSERM) 1052 Centre national de la recherche scientifique (CNRS) 5286, Lyon, France; Université Claude Bernard, Université de Lyon, Lyon, France. Electronic address:

Introduction: Sequential anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) followed by small targeted therapy use is associated with increased prevalence of adverse events (AEs) in NSCLC. KRASG12C inhibitor sotorasib may trigger severe immune-mediated hepatotoxicity when used in sequence or in combination with anti-PD-(L)1. This study was designed to address whether sequential anti-PD-(L)1 and sotorasib therapy increases the risk of hepatotoxicity and other AEs.

View Article and Find Full Text PDF

Effect of a lifestyle intervention to prevent weight gain at initiation of insulin pump therapy in type 2 diabetes: A randomized, controlled, multicentre trial.

Diabetes Res Clin Pract

June 2023

Univ. Grenoble Alpes, INSERM U1300, CHU Grenoble Alpes, Department of Endocrinology, Diabetology and Nutrition, 38000 Grenoble, France. Electronic address:

Unlabelled: Insulin pump therapy improves glycaemic control in individuals with type 2 diabetes. However, it may be associated with weight gain.

Aim: To test the effectiveness of a six-month dietary and physical activity intervention, compared to usual care, on weight gain prevention after initiation of insulin pump.

View Article and Find Full Text PDF
Article Synopsis
  • Molecular recurrence (MRec) affects about 50% of chronic myeloid leukaemia (CML) patients who stop taking tyrosine kinase inhibitors (TKI) and occurs despite achieving sustained deep molecular responses.
  • In a study involving 31 patients, 23 who switched to nilotinib (300 mg twice daily) maintained their molecular response for an average of 22 months, while seven experienced serious side effects leading to treatment discontinuation.
  • The study found that 59.1% of patients remained treatment-free and maintained molecular response 24 months after stopping nilotinib, and 42.1% maintained it at 48 months, indicating promising results
View Article and Find Full Text PDF
Article Synopsis
  • A study called the NUTRIREA-3 trial explored whether lower calorie and protein intake during the early treatment of critically ill patients could lead to better outcomes compared to standard nutrition guidelines.
  • Conducted in 61 ICUs across France, the trial involved over 3,000 patients who received either low or standard nutrition after being put on mechanical ventilation for shock.
  • Results showed no significant difference in 90-day mortality rates but indicated that patients on the low nutrition plan had a slightly quicker ICU discharge time and experienced fewer gastrointestinal issues and liver dysfunction.
View Article and Find Full Text PDF

Occurrence of focal myositis during Behçet's disease: The identification of a specific vasculitis-associated focal myopathy.

Neuropathol Appl Neurobiol

April 2023

Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, Centre National de Références Maladies Autoimmunes Systémiques Rares, Centre National de Références Maladies Autoinflammatoires et Amylose Inflammatoire; Inflammation-Immunopathology-Biotherapy Department (DMU 3iD); INSERM 959, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France.

Aims: This study aimed to report the association of focal myositis (FM) and Behçet's disease (BD) and to analyse the main characteristics of such an association.

Methods: This is a retrospective multicentre study of patients with BD and FM (BD + FM+ group) and those without FM (BD - FM+ group). Clinical, laboratory, radiological, pathological, treatment and outcome data were analysed.

View Article and Find Full Text PDF

Objective: The aim of this study was to evaluate the outcomes of different surgical strategies for acute Stanford type A aortic dissection (TAAD).

Summary Background Data: The optimal extent of aortic resection during surgery for acute TAAD is controversial.

Methods: This is a multicenter, retrospective cohort study of patients who underwent surgery for acute TAAD at 18 European hospitals.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the prevalence and incidence of hepatitis E virus (HEV) infection in patients with inflammatory bowel disease (IBD) undergoing immunomodulatory treatment, given that these medications can compromise the immune system.
  • Conducted across 16 French centers, the research involved 488 IBD patients, revealing very few cases of acute HEV infection, with a seroprevalence of 14.2% for chronic infection, particularly among older patients and those with higher seafood intake.
  • The findings suggest that routine HEV screening isn't necessary for IBD patients on immunomodulators, but HEV should be tested if liver abnormalities occur.
View Article and Find Full Text PDF

Purpose: To evaluate the impact of individual institutions on the outcome after surgery for Stanford type A aortic dissection (TAAD).

Methods: This is an observational, multicenter, retrospective cohort study including 3902 patients who underwent surgery for TAAD at 18 university and non-university hospitals.

Results: Logistic regression showed that four hospitals had increased risk of in-hospital mortality, while two hospitals were associated with decreased risk of in-hospital mortality.

View Article and Find Full Text PDF

Background: The optimal duration of antimicrobial therapy for urinary tract infections (UTIs) in men remains controversial.

Methods: To compare 7 days to 14 days of total antibiotic treatment for febrile UTIs in men, this multicenter randomized, double-blind. placebo-controlled noninferiority trial enrolled 282 men from 27 centers in France.

View Article and Find Full Text PDF

Background: The objective of the CHEOPS trial was to assess the benefit of adding aromatase inhibitor (AI) to metronomic chemotherapy, oral vinorelbine, 50 mg, three times a week for pre-treated, HR + /HER2- metastatic breast cancer patients.

Methods: In this multicentric phase II study, patients had to have progressed on AI and one or two lines of chemotherapy. They were randomized between oral vinorelbine (Arm A) and oral vinorelbine with non-steroidal AI (Arm B).

View Article and Find Full Text PDF

Objectives: The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients.

Methods: We conducted an international, multi-centric, retrospective study in 14 centres (Bulgaria, Croatia, France, and Turkey).

View Article and Find Full Text PDF

Background: Treating pneumonia in old patients remains challenging for clinicians. Moreover, bacterial antimicrobial resistance is a major public health threat.

Objective: The PROPAGE study evaluated the interest of a strategy using serial measurements of procalcitonin (PCT) to reduce the duration of antibiotic therapy in old patients with pneumonia.

View Article and Find Full Text PDF

Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination.

View Article and Find Full Text PDF

Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.

Eur J Cancer

January 2023

Gustave Roussy - Paris-Saclay University, Département d'Innovation Thérapeutique et Essais Précoces, 94800 Villejuif, France; Gustave Roussy, INSERM U1170, Université Paris-Saclay, Villejuif, France. Electronic address:

Background: Generalised oedema was occasionally reported associated with immune checkpoint inhibitors (ICPIs). The purpose of this study is to investigate immune-related generalised oedema (ir-GE) drug related to ICPI, through frequency, clinical and pathological characteristics, and patient's outcome.

Patients And Methods: Objectives of the study were to report on ir-GE associated with ICPI to define frequency, associated signs and symptoms, pathological characteristics, severity, and response to corticosteroids.

View Article and Find Full Text PDF

(1) Background: Acute Stanford type A aortic dissection (TAAD) may complicate the outcome of cardiovascular procedures. Data on the outcome after surgery for iatrogenic acute TAAD is scarce. (2) Methods: The European Registry of Type A Aortic Dissection (ERTAAD) is a multicenter, retrospective study including patients who underwent surgery for acute TAAD at 18 hospitals from eight European countries.

View Article and Find Full Text PDF

Machine learning-based scoring system to predict in-hospital outcomes in patients hospitalized with COVID-19.

Arch Cardiovasc Dis

December 2022

Université de Paris, PARCC, INSERM, 75015 Paris, France; Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France.

Background: The evolution of patients hospitalized with coronavirus disease 2019 (COVID-19) is still hard to predict, even after several months of dealing with the pandemic.

Aims: To develop and validate a score to predict outcomes in patients hospitalized with COVID-19.

Methods: All consecutive adults hospitalized for COVID-19 from February to April 2020 were included in a nationwide observational study.

View Article and Find Full Text PDF

Background: Given the rapidly evolving pandemic of COVID-19 in 2020, authorities focused on the repurposing of available drugs to develop timely and cost-effective therapeutic strategies. Evidence suggested the potential utility of remdesivir in the framework of an early access program. REMDECO-19 is a multicenter national cohort study assessing the ability of remdesivir to improve the outcome of patients hospitalized with COVID-19.

View Article and Find Full Text PDF

Background and aims: Pancreatic cancer is highly lethal and often diagnosed at an advanced stage. This cohort study analyzes the impact of care pathways, delays, and socio-spatial determinants on pancreatic cancer patients’ diagnosis, treatment, and prognosis. Method: Patients with pancreatic adenocarcinoma newly diagnosed at all stages between January and June 2016 in the AuRA French region were included.

View Article and Find Full Text PDF